Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis
Authors:
- 5 November 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (17) , 1362-1373
Abstract
Aims: Calcific aortic valve stenosis (CAVS) is characterized by a fibrocalcific process. Studies have shown an association between CAVS and the activation of platelets. It is believed that shear stress associated with CAVS promotes the activation of platelets. However, whether platelets actively participate to the mineralization of the aortic valve (AV) and the progression of CAVS is presently unknown. To identify the role of platelets into the pathobiology of CAVS. Methods and results: Explanted control non-mineralized and mineralized AVs were examined by scanning electron microscope (SEM) for the presence of activated platelets. In-depth functional assays were carried out with isolated human valve interstitial cells (VICs) and platelets as well as in LDLR−/− apoB100/100 IGFII (IGFII) mice. Scanning electron microscope and immunogold markings for glycoprotein IIb/IIIa (GPIIb/IIIa) revealed the presence of platelet aggregates with fibrin in endothelium-denuded areas of CAVS. In isolated VICs, collagen-activated platelets induced an osteogenic programme. Platelet-derived adenosine diphosphate induced the release of autotaxin (ATX) by VICs. The binding of ATX to GPIIb/IIIa of platelets generated lysophosphatidic acid (LysoPA) with pro-osteogenic properties. In IGFII mice with CAVS, platelet aggregates were found at the surface of AVs. Administration of activated platelets to IGFII mice accelerated the development of CAVS by 2.1-fold, whereas a treatment with Ki16425, an antagonist of LysoPA receptors, prevented platelet-induced mineralization of the AV and the progression of CAVS. Conclusions: These findings suggest a novel role for platelets in the progression of CAVS.Keywords
Funding Information
- Canadian Institutes of Health Research (FRN114893)
- Canadian Institutes of Health Research (FRN142244)
- Canadian Institutes of Health Research (FRN148778)
- Canadian Institutes of Health Research (FRN130254)
- Canadian Institutes of Health Research (FDN-143247)
- Heart and Stroke Foundation of Canada (G-14-0005913)
- Quebec Heart and Lung Institute Fund
- Canada Research Chair in Genomics of Heart and Lung Diseases
- Canada Research Chair in Heart Valve Disease
- Canadian Institutes of Health Research
- Fonds de recherche du Québec-Santé
- Santé
- Research Chair on the Pathobiology of Calcific Aortic Valve Disease
This publication has 30 references indexed in Scilit:
- The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulationJournal of Lipid Research, 2011
- Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor–thrombin pathway and potential role through osteopontin alterationAtherosclerosis, 2010
- Evidence for tissue factor expression in aortic valves in patients with aortic stenosisPolish Archives of Internal Medicine, 2009
- Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and ThrombosisJournal of Biological Chemistry, 2009
- Recurrent systemic embolism caused by thrombosis in a stenotic bicuspid aortic valve.European Heart Journal - Cardiovascular Imaging, 2008
- Increased levels of circulating microparticles in patients with severe aortic valve stenosisThrombosis and Haemostasis, 2008
- Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis.2006
- Acquired von Willebrand Syndrome in Aortic StenosisNew England Journal of Medicine, 2003
- Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein ENature Medicine, 2002
- Ultrastructural alterations of endothelium covering advanced atherosclerotic plaque in human carotid artery visualised by scanning electron microscope.2002